Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03435003 · ClinicalTrials.gov registry record · Phase 4
Designing Optimal Prevention and Management of Postoperative Nausea and Emesis for Patients Undergoing Laparoscopic Sleeve Gastrectomy
A Phase 4 study, sponsored by Stony Brook University.
- Completed
- Registry status
- Phase 4
- Development phase
- 83
- Enrollment target
NCT03435003 is a Phase 4 study that has completed, run by Stony Brook University. The registered enrollment target is 83 participants.
The verdict
NCT03435003, a Phase 4 study, has completed, sponsored by Stony Brook University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 83 participants
- Enrollment target
Study Summary
Bariatric surgery remains the most effective therapy for obesity. Postoperative nausea and vomiting (PONV) are commonly reported following bariatric surgery. The proposed study focuses on the most common bariatric procedure performed, laparoscopic sleeve gastrectomy (LSG), and aims to assess the effect of a post-operative nausea and vomiting-specific intervention. The investigators hypothesize that the intervention group will experience a reduction of nausea-related prolonged hospital stay and significantly improve patient-reported quality of recovery from surgery and quality of life.
Interventions
- DRUG Dexamethasone
- DRUG Ondansetron
- DRUG Aprepitant 80 mg Oral Capsule
- DRUG scopolamine transdermal
- PROCEDURE Total intravenous anesthesia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2017-08-28 |
| Est. Completion | 2019-04-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03435003
The ClinicalTrials.gov registry entry for NCT03435003 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 83 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stony Brook University, which has 127 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Dexamethasone is the first listed.
NCT03435003 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03435003 about?
NCT03435003 is a clinical study titled "Designing Optimal Prevention and Management of Postoperative Nausea and Emesis for Patients Undergoing Laparoscopic Sleeve Gastrectomy". Bariatric surgery remains the most effective therapy for obesity. Postoperative nausea and vomiting (PONV) are commonly reported following bariatric surgery. The proposed study focuses on the most common bariatric procedure performed, laparoscopic sleeve gastrectomy (LSG), and aims to assess the eff...
What is the current status of trial NCT03435003?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 83 participants. The study started on 2017-08-28. Estimated completion is 2019-04-01.
What interventions are being tested in trial NCT03435003?
The interventions under investigation include: Dexamethasone (DRUG), Ondansetron (DRUG), Aprepitant 80 mg Oral Capsule (DRUG), scopolamine transdermal (DRUG), Total intravenous anesthesia (PROCEDURE).
Who is sponsoring clinical trial NCT03435003?
This trial is sponsored by Stony Brook University, which has 127 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.